Associations - BRCA1 mutation

BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval AstraZeneca Press Release - 1 week	olaparib Sensitive: A1 - Approval AstraZeneca Press Release - 1 week
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	pamiparib Sensitive: A1 - Approval Clin Cancer Res - 1 week	pamiparib Sensitive: A1 - Approval Clin Cancer Res - 1 week
BRCA1 mutation BRCA1 mutation	Breast Cancer Breast Cancer	BRCA1 mutation BRCA1 mutation	Breast Cancer Breast Cancer	ABT-888 Sensitive: B - Late Trials Ann Oncol - 1 week	ABT-888 Sensitive: B - Late Trials Ann Oncol - 1 week
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	olaparib Sensitive: A1 - Approval Cancer Discov - 2 weeks	olaparib Sensitive: A1 - Approval Cancer Discov - 2 weeks
BRCA1 mutation BRCA1 mutation	Pancreatic Cancer Pancreatic Cancer	BRCA1 mutation BRCA1 mutation	Pancreatic Cancer Pancreatic Cancer	olaparib Sensitive: A1 - Approval	olaparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Peritoneal Cancer Peritoneal Cancer	BRCA1 mutation BRCA1 mutation	Peritoneal Cancer Peritoneal Cancer	olaparib + bevacizumab Sensitive: A1 - Approval	olaparib + bevacizumab Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Peritoneal Cancer Peritoneal Cancer	BRCA1 mutation BRCA1 mutation	Peritoneal Cancer Peritoneal Cancer	rucaparib Sensitive: A1 - Approval	rucaparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Fallopian Tube Cancer Fallopian Tube Cancer	BRCA1 mutation BRCA1 mutation	Fallopian Tube Cancer Fallopian Tube Cancer	rucaparib Sensitive: A1 - Approval	rucaparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Fallopian Tube Cancer Fallopian Tube Cancer	BRCA1 mutation BRCA1 mutation	Fallopian Tube Cancer Fallopian Tube Cancer	olaparib + bevacizumab Sensitive: A1 - Approval	olaparib + bevacizumab Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Peritoneal Cancer Peritoneal Cancer	BRCA1 mutation BRCA1 mutation	Peritoneal Cancer Peritoneal Cancer	niraparib Sensitive: A1 - Approval	niraparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Fallopian Tube Cancer Fallopian Tube Cancer	BRCA1 mutation BRCA1 mutation	Fallopian Tube Cancer Fallopian Tube Cancer	niraparib Sensitive: A1 - Approval	niraparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Fallopian Tube Cancer Fallopian Tube Cancer	BRCA1 mutation BRCA1 mutation	Fallopian Tube Cancer Fallopian Tube Cancer	olaparib Sensitive: A1 - Approval	olaparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Peritoneal Cancer Peritoneal Cancer	BRCA1 mutation BRCA1 mutation	Peritoneal Cancer Peritoneal Cancer	olaparib Sensitive: A1 - Approval	olaparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Prostate Cancer Prostate Cancer	BRCA1 mutation BRCA1 mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A1 - Approval	olaparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	rucaparib Sensitive: A1 - Approval	rucaparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	olaparib + bevacizumab Sensitive: A1 - Approval	olaparib + bevacizumab Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Fallopian Tube Cancer Fallopian Tube Cancer	BRCA1 mutation BRCA1 mutation	Fallopian Tube Cancer Fallopian Tube Cancer	pamiparib Sensitive: A1 - Approval	pamiparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	niraparib Sensitive: A1 - Approval	niraparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	talazoparib Sensitive: A1 - Approval	talazoparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Prostate Cancer Prostate Cancer	BRCA1 mutation BRCA1 mutation	Prostate Cancer Prostate Cancer	rucaparib Sensitive: A1 - Approval	rucaparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Peritoneal Cancer Peritoneal Cancer	BRCA1 mutation BRCA1 mutation	Peritoneal Cancer Peritoneal Cancer	pamiparib Sensitive: A1 - Approval	pamiparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	BRCA1 mutation BRCA1 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	cisplatin + gemcitabine Sensitive: A2 - Guideline	cisplatin + gemcitabine Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	bevacizumab Resistant: A2 - Guideline	bevacizumab Resistant: A2 - Guideline
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PARP inhibitor Sensitive: A2 - Guideline	PARP inhibitor Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Breast Cancer Breast Cancer	BRCA1 mutation BRCA1 mutation	Breast Cancer Breast Cancer	talazoparib Sensitive: A2 - Guideline	talazoparib Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	cisplatin Sensitive: A2 - Guideline	cisplatin Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	carboplatin Sensitive: A2 - Guideline	carboplatin Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	gemcitabine Sensitive: A2 - Guideline	gemcitabine Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	capecitabine Sensitive: A2 - Guideline	capecitabine Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	vinorelbine tartrate Sensitive: A2 - Guideline	vinorelbine tartrate Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline	eribulin mesylate Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	pegylated liposomal doxorubicin Sensitive: A2 - Guideline	pegylated liposomal doxorubicin Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	olaparib Sensitive: A2 - Guideline	olaparib Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Breast Cancer Breast Cancer	BRCA1 mutation BRCA1 mutation	Breast Cancer Breast Cancer	olaparib Sensitive: A2 - Guideline	olaparib Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	talazoparib Sensitive: A2 - Guideline	talazoparib Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	PARP inhibitor Sensitive: A2 - Guideline	PARP inhibitor Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	doxorubicin hydrochloride Sensitive: A2 - Guideline	doxorubicin hydrochloride Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	paclitaxel Sensitive: A2 - Guideline	paclitaxel Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	BRCA1 mutation BRCA1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	PARP inhibitor Sensitive: A2 - Guideline	PARP inhibitor Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Prostate Cancer Prostate Cancer	BRCA1 mutation BRCA1 mutation	Prostate Cancer Prostate Cancer	niraparib Sensitive: B - Late Trials	niraparib Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	CaT Sensitive: B - Late Trials	CaT Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	ABT-888 Sensitive: B - Late Trials	ABT-888 Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ABT-888 Sensitive: B - Late Trials	ABT-888 Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	atezolizumab Sensitive: B - Late Trials	atezolizumab Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	olaparib + cediranib Sensitive: B - Late Trials	olaparib + cediranib Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	trabectedin Sensitive: B - Late Trials	trabectedin Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	PARP inhibitor Sensitive: B - Late Trials	PARP inhibitor Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	BRCA1 mutation BRCA1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	ABT-888 Sensitive: B - Late Trials	ABT-888 Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	ABT-888 Sensitive: B - Late Trials	ABT-888 Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	fluzoparib Sensitive: B - Late Trials	fluzoparib Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Breast Cancer Breast Cancer	BRCA1 mutation BRCA1 mutation	Breast Cancer Breast Cancer	ribociclib Sensitive: B - Late Trials	ribociclib Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	BRCA1 mutation BRCA1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	talazoparib Sensitive: B - Late Trials	talazoparib Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	atezolizumab Resistant: B - Late Trials	atezolizumab Resistant: B - Late Trials
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	CPB Sensitive: B - Late Trials	CPB Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	rucaparib Resistant: B - Late Trials	rucaparib Resistant: B - Late Trials
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	niraparib Sensitive: B - Late Trials	niraparib Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Non Small Cell Lung Cancer NSCLC	BRCA1 mutation BRCA1 mutation	Non Small Cell Lung Cancer NSCLC	rucaparib Sensitive: C1 - Off-label	rucaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Cholangiocarcinoma Cholangiocarcinoma	BRCA1 mutation BRCA1 mutation	Cholangiocarcinoma Cholangiocarcinoma	olaparib Sensitive: C1 - Off-label	olaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Pancreatic Cancer Pancreatic Cancer	BRCA1 mutation BRCA1 mutation	Pancreatic Cancer Pancreatic Cancer	rucaparib Sensitive: C1 - Off-label	rucaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	niraparib Sensitive: C1 - Off-label	niraparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Endometrial Cancer Endometrial Cancer	BRCA1 mutation BRCA1 mutation	Endometrial Cancer Endometrial Cancer	olaparib Sensitive: C1 - Off-label	olaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Mesothelioma Mesothelioma	BRCA1 mutation BRCA1 mutation	Mesothelioma Mesothelioma	rucaparib Sensitive: C1 - Off-label	rucaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Germ Cell Tumors Germ Cell Tumors	BRCA1 mutation BRCA1 mutation	Germ Cell Tumors Germ Cell Tumors	olaparib Sensitive: C1 - Off-label	olaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	rucaparib Sensitive: C1 - Off-label	rucaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	BRCA1 mutation BRCA1 mutation	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	olaparib Sensitive: C1 - Off-label	olaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	pamiparib Sensitive: C1 - Off-label	pamiparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	talazoparib Sensitive: C1 - Off-label	talazoparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Colorectal Cancer CRC	BRCA1 mutation BRCA1 mutation	Colorectal Cancer CRC	olaparib Sensitive: C1 - Off-label	olaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Prostate Cancer Prostate Cancer	BRCA1 mutation BRCA1 mutation	Prostate Cancer Prostate Cancer	talazoparib Sensitive: C1 - Off-label	talazoparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Renal Cell Carcinoma RCC	BRCA1 mutation BRCA1 mutation	Renal Cell Carcinoma RCC	olaparib Sensitive: C1 - Off-label	olaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Endometrial Cancer Endometrial Cancer	BRCA1 mutation BRCA1 mutation	Endometrial Cancer Endometrial Cancer	niraparib Sensitive: C1 - Off-label	niraparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	BRCA1 mutation BRCA1 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C1 - Off-label	olaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Gallbladder Cancer Gallbladder Cancer	BRCA1 mutation BRCA1 mutation	Gallbladder Cancer Gallbladder Cancer	olaparib Sensitive: C1 - Off-label	olaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	tislelizumab + pamiparib Sensitive: C2 – Inclusion Criteria	tislelizumab + pamiparib Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Pancreatic Cancer Pancreatic Cancer	BRCA1 mutation BRCA1 mutation	Pancreatic Cancer Pancreatic Cancer	ABT-888 Sensitive: C2 – Inclusion Criteria	ABT-888 Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	BRCA1 mutation BRCA1 mutation	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	olaparib + LY2606368 Sensitive: C2 – Inclusion Criteria	olaparib + LY2606368 Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	olaparib + CP-675206 Sensitive: C2 – Inclusion Criteria	olaparib + CP-675206 Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	olaparib + bevacizumab + durvalumab Sensitive: C2 – Inclusion Criteria	olaparib + bevacizumab + durvalumab Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	carboplatin + paclitaxel Sensitive: C2 – Inclusion Criteria	carboplatin + paclitaxel Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	IMP4297 Sensitive: C2 – Inclusion Criteria	IMP4297 Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib + durvalumab Sensitive: C2 – Inclusion Criteria	olaparib + durvalumab Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	SC10914 Sensitive: C2 – Inclusion Criteria	SC10914 Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Breast Cancer Breast Cancer	BRCA1 mutation BRCA1 mutation	Breast Cancer Breast Cancer	olaparib + AZD5363 Sensitive: C2 – Inclusion Criteria	olaparib + AZD5363 Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	olaparib + durvalumab Sensitive: C2 – Inclusion Criteria	olaparib + durvalumab Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	tislelizumab + pamiparib Sensitive: C2 – Inclusion Criteria	tislelizumab + pamiparib Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	olaparib + durvalumab + CP-675206 Sensitive: C2 – Inclusion Criteria	olaparib + durvalumab + CP-675206 Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Solid Tumor Solid Tumor	BRCA1 mutation BRCA1 mutation	Solid Tumor Solid Tumor	avelumab Sensitive: C2 – Inclusion Criteria	avelumab Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Prostate Cancer Prostate Cancer	BRCA1 mutation BRCA1 mutation	Prostate Cancer Prostate Cancer	pembrolizumab Sensitive: C2 – Inclusion Criteria	pembrolizumab Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	olaparib Sensitive: C2 – Inclusion Criteria	olaparib Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	gemcitabine + eribulin mesylate Resistant: C3 – Early Trials	gemcitabine + eribulin mesylate Resistant: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab + niraparib Sensitive: C3 – Early Trials	pembrolizumab + niraparib Sensitive: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib + AZD6738 Sensitive: C3 – Early Trials	olaparib + AZD6738 Sensitive: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	BRCA1 mutation BRCA1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	fulvestrant + anastrozole Resistant: C3 – Early Trials	fulvestrant + anastrozole Resistant: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	BRCA1 mutation BRCA1 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials	FOLFIRINOX Sensitive: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BAY1895344 Sensitive: C3 – Early Trials	BAY1895344 Sensitive: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	Pancreatic Cancer Pancreatic Cancer	BRCA1 mutation BRCA1 mutation	Pancreatic Cancer Pancreatic Cancer	oxaliplatin Sensitive: C3 – Early Trials	oxaliplatin Sensitive: C3 – Early Trials